WO2023223292 - METHODS OF PRODUCING ENGINEERED IMMUNE CELLS
National phase entry is expected:
Publication Number
WO/2023/223292
Publication Date
23.11.2023
International Application No.
PCT/IB2023/055198
International Filing Date
19.05.2023
Title **
[English]
METHODS OF PRODUCING ENGINEERED IMMUNE CELLS
[French]
MÉTHODES DE PRODUCTION DE CELLULES IMMUNITAIRES MODIFIÉES
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
OGAKI, Soichiro
ARAKI, Hideo
NAKAMURA, Yoshiki
MAEDA, Eiki
Priority Data
63/344,255
20.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2148 | |
| EPO | Filing, Examination, Granting | 9180 | |
| Japan | Filing, Examination, Granting | 2006 | |
| South Korea | Filing, Examination, Granting | 1747 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,821
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides improved methods of producing engineered T cells that express an exogenous gene (e.g., CAR-T cells). T cells that express an exogenous gene and compositions comprising the same of the present technology are useful for treating various diseases, e.g., infection, autoimmune diseases, and tumors.[French]
La présente divulgation concerne des méthodes perfectionnées de production de lymphocytes T modifiés qui expriment un gène exogène (par exemple, des cellules CAR-T). Des lymphocytes T qui expriment un gène exogène et des compositions les comprenant sont utiles pour traiter diverses maladies, par exemple, une infection, des maladies auto-immunes et des tumeurs.